D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $34 Price Target

NRX Pharmaceuticals, Inc. -0.40% Post

NRX Pharmaceuticals, Inc.

NRXP

2.51

2.53

-0.40%

+0.80% Post
D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ: NRXP) with a Buy and maintains $34 price target.